Robert J. Nordyke
University of California, Los Angeles
Physical therapyAsthmaCOPDSpirometryMedicine
What is this?
Publications 38
#1Robert J. NordykeH-Index: 16
#2Chih-Hung ChangH-Index: 33
Last. Lee S. SchwartzbergH-Index: 41
view all 6 authors...
Objective Robust cost estimates of cardiovascular (CV) events are required for assessing health care interventions aimed at reducing the economic burden of major adverse CV events. This review synthesizes international cost estimates of CV events.
16 CitationsSource
#1A. WangH-Index: 2
#2Akshara Richhariya (Seattle Genetics)H-Index: 3
Last. Peter P. Toth (UIC: University of Illinois at Chicago)H-Index: 37
view all 8 authors...
Background Apheresis is an important treatment for reducing low‐density lipoprotein cholesterol (LDL‐C) in patients with familial hypercholesterolemia (FH). We systematically reviewed the current literature surrounding LDL‐C apheresis for FH. Methods and Results Electronic databases were searched for publications of LDL‐C apheresis in patients with FH. Inclusion criteria include articles in English published in 2000–2013 that provide descriptions of practice patterns, efficacy/effectiveness, and...
21 CitationsSource
OBJECTIVES: Chronic obstructive pulmonary disease (COPD) as a cause of disability with subsequent costs remains poorly recognized. The small, growing body of literature on COPD shows that it is one of the leading causes of missed work—greater than asthma or diabetes. However, much less is known about the impact of COPD on long-term disability (LTD). Because the health care burden for disabled, working-age patients will fall heavily on managed care organizations,better estimates of the economic a...
15 CitationsSource
#1Beth L. NordstromH-Index: 14
#2Weixiu LuoH-Index: 3
Last. Robert J. NordykeH-Index: 16
view all 5 authors...
BACKGROUND: Prior to 2007, the erythropoiesis-stimulating agents (ESAs) epoetin alfa and darbepoetin alfa were indicated for use in chemotherapy induced anemia to achieve target hemoglobin (Hb) levels of approximately 12 grams per deciliter (gm per dL), and treatment was to be withheld if Hb exceeded 13 gm per dL. In March 2007, the FDA changed the labeling of the ESAs to add boxed warnings, updated in November 2007, to include the following key points: (a) ESAs should be used only to treat anem...
11 CitationsSource
#1A. WangH-Index: 2
#2A. Richhariya (Amgen)H-Index: 1
Last. Robert J. NordykeH-Index: 16
view all 6 authors...
#2R.J. HalbertH-Index: 23
Last. Shravanthi R. Gandra (Amgen)H-Index: 19
view all 7 authors...
#1A. WangH-Index: 2
#2R.J. HalbertH-Index: 23
Last. Robert J. NordykeH-Index: 16
view all 4 authors...
To improve formulary design processes and support payers in providing more effective health care, policy makers should consider involving commercial payers in the development of comparative effectiveness research and creation of research and treatment guidelines.
7 CitationsSource
#1A. WangH-Index: 2
#2T. BaerwaldtH-Index: 1
Last. R.J. HalbertH-Index: 23
view all 5 authors...
1 CitationsSource
#1Ninez A. Ponce (UCLA: University of California, Los Angeles)H-Index: 26
#2Aimee Afable-Munsuz (UCSF: University of California, San Francisco)H-Index: 11
Last. Robert J. Nordyke (UCLA: University of California, Los Angeles)H-Index: 16
view all 3 authors...
Testing for germ-line mutations offers a predictive tool of hereditary cancer risk with the promise of future benefits to the US healthcare system and its consumers. Based on the few studies on genetic testing for cancer, awareness and uptake appear to be lower among racial/ethnic minorities. The sources of variation need to be understood for ethical reasons and for more successful technology diffusion in the broader population. We conceptualise a framework for the impact of genetic testing on d...
3 CitationsSource